Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Kwang Hyun Kim, Sey Kiat Lim, Tae Young Shin, Byung Ha Chung, Sung Joon Hong, Koon Ho Rha

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml-1 (IQR: 5.14-11.45) and 39.2% of the patients were classified as intermediate risk and 15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5% and 14.2% had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P<0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years following RARP, respectively (P<0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.

Original languageEnglish
Pages (from-to)404-408
Number of pages5
JournalAsian Journal of Andrology
Volume15
Issue number3
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Neoplasm Grading
Prostatectomy
Recurrence
Survival Rate
Prostate-Specific Antigen
Neoadjuvant Therapy
Robotics
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Kim, Kwang Hyun ; Lim, Sey Kiat ; Shin, Tae Young ; Chung, Byung Ha ; Hong, Sung Joon ; Rha, Koon Ho. / Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years. In: Asian Journal of Andrology. 2013 ; Vol. 15, No. 3. pp. 404-408.
@article{6a044b33558a42d08640a07135f5f06c,
title = "Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years",
abstract = "In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml-1 (IQR: 5.14-11.45) and 39.2{\%} of the patients were classified as intermediate risk and 15.3{\%} were classified as high risk; on final pathological examination, 35.2{\%} of the patients had non-organ confined disease and 37.5{\%} and 14.2{\%} had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6{\%} and 81.2{\%}, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1{\%} in Gleason scores of 6 or less, 74.5{\%} in a Gleason score of 7, and 58.1{\%} in Gleason scores of 8 or greater, respectively (P<0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8{\%} in pT2 patients, 66.2{\%} in pT3a patients, and 39.3{\%} in pT3b patients at 5 years following RARP, respectively (P<0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.",
author = "Kim, {Kwang Hyun} and Lim, {Sey Kiat} and Shin, {Tae Young} and Chung, {Byung Ha} and Hong, {Sung Joon} and Rha, {Koon Ho}",
year = "2013",
month = "5",
day = "1",
doi = "10.1038/aja.2013.5",
language = "English",
volume = "15",
pages = "404--408",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "3",

}

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years. / Kim, Kwang Hyun; Lim, Sey Kiat; Shin, Tae Young; Chung, Byung Ha; Hong, Sung Joon; Rha, Koon Ho.

In: Asian Journal of Andrology, Vol. 15, No. 3, 01.05.2013, p. 404-408.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

AU - Kim, Kwang Hyun

AU - Lim, Sey Kiat

AU - Shin, Tae Young

AU - Chung, Byung Ha

AU - Hong, Sung Joon

AU - Rha, Koon Ho

PY - 2013/5/1

Y1 - 2013/5/1

N2 - In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml-1 (IQR: 5.14-11.45) and 39.2% of the patients were classified as intermediate risk and 15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5% and 14.2% had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P<0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years following RARP, respectively (P<0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.

AB - In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml-1 (IQR: 5.14-11.45) and 39.2% of the patients were classified as intermediate risk and 15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5% and 14.2% had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P<0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years following RARP, respectively (P<0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84877246486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877246486&partnerID=8YFLogxK

U2 - 10.1038/aja.2013.5

DO - 10.1038/aja.2013.5

M3 - Article

C2 - 23524532

AN - SCOPUS:84877246486

VL - 15

SP - 404

EP - 408

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 3

ER -